Molecular characterization of 103 ovarian serous and mucinous tumors
- PMID: 21136228
- DOI: 10.1007/s12253-010-9345-8
Molecular characterization of 103 ovarian serous and mucinous tumors
Abstract
The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60% of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a "dualistic" model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100% of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.
Similar articles
-
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.Am J Surg Pathol. 2007 Jul;31(7):1007-12. doi: 10.1097/PAS.0b013e31802cbbe9. Am J Surg Pathol. 2007. PMID: 17592266
-
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232
-
Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.Pathol Int. 2013 May;63(5):252-9. doi: 10.1111/pin.12060. Pathol Int. 2013. PMID: 23714252
-
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Adv Anat Pathol. 2009. PMID: 19700937 Free PMC article. Review.
-
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25573350 Review.
Cited by
-
Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.Diagn Pathol. 2021 Mar 11;16(1):20. doi: 10.1186/s13000-021-01079-2. Diagn Pathol. 2021. PMID: 33706757 Free PMC article. Review.
-
Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications.Cells. 2021 Sep 1;10(9):2272. doi: 10.3390/cells10092272. Cells. 2021. PMID: 34571921 Free PMC article. Review.
-
KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.BMC Cancer. 2013 Oct 18;13:483. doi: 10.1186/1471-2407-13-483. BMC Cancer. 2013. PMID: 24139521 Free PMC article.
-
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.Neoplasia. 2019 Jun;21(6):582-590. doi: 10.1016/j.neo.2019.03.014. Epub 2019 May 1. Neoplasia. 2019. PMID: 31054497 Free PMC article.
-
The expression profiles of chemokines, innate immune and apoptotic genes in tumors caused by Rous Sarcoma Virus (RSV-A) in chickens.Genes Immun. 2022 Feb;23(1):12-22. doi: 10.1038/s41435-021-00158-0. Epub 2021 Dec 21. Genes Immun. 2022. PMID: 34934184
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous